Neutro Pharma (Pvt.) Ltd.,
Private pharmaceutical and nutraceutical manufacturer · Lahore · Pakistan
Lahore-based pharmaceutical and wellness company manufacturing pharmaceuticals, nutraceuticals and specialty healthcare products.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Neutro Pharma (Pvt.) Ltd.
- Company type
- Private pharmaceutical and nutraceutical manufacturer
- Address
- 23-M, Gulberg III, Lahore, Pakistan
- Website
- neutropharma.com ↗
- Phone
- +92 42 37339087-89
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Neurivox | Rivaroxaban | 15 mg | Tablet | 10's | 095593 | PKR 7,051.08 | PKR 705.11/tablet | Near median |
| Neurivox | Rivaroxaban | 15 mg | Tablet | 14's | 095593 | PKR 9,871.52 | PKR 705.11/tablet | Near median |
| Neurivox | Rivaroxaban | 20 mg | Tablet | 7's | 095594 | PKR 6,576.18 | PKR 939.45/tablet | 5% above median |
| Neusetro | Ondansetron | 2 mg/mL | Injection | 5'sx4mlLDPE | 109653 | PKR 3,879.25 | — | No comparator |
| Neusold | Sodium chloride | 0.9 g | IV infusion | 100ml | 088579 | PKR 75.80 | PKR 0.76/mL | 58% above median |
| Neusold | Sodium chloride | 0.9% w/v | IV infusion | 500ml | 093748 | PKR 71.81 | PKR 0.14/mL | 43% below median |
| Neustore 10 | Dextrose | 10 g/100 mL | IV infusion | 500ml | 086330 | PKR 138.44 | PKR 0.28/mL | 65% above median |
| Neustore 10 (1000 ml) | Dextrose | 10% | IV infusion | 1000ml | 086331 | PKR 194.14 | PKR 0.19/mL | 8% below median |
| Neustore 5 | Dextrose Anhydrous | 5 g/100 mL | IV infusion | 500ml | 086328 | PKR 139.85 | PKR 0.28/mL | No comparator |
| Neustore 5 (100 ml) | Dextrose | 5 g | IV infusion | 100ml | 086327 | PKR 92.01 | PKR 0.92/mL | 444% above median |
| Neustore 5 (1000 ml) | Dextrose | 5 g | IV infusion | 1000ml | 086329 | PKR 169.29 | PKR 0.17/mL | 82% below median |
| Neutacroli | Tacrolimus | 1 mg | Capsule | 50's | 091495 | PKR 4,890.50 | PKR 97.81/capsule | Near median |
| Neutacroli | Tacrolimus | 0.5 mg | Capsule | 10's | 097629 | PKR 626.67 | PKR 62.67/capsule | 10% above median |
| Neutamiv | Oseltamivir | 75 mg | Capsule | 10's | 101916 | PKR 1,204.29 | PKR 120.43/capsule | Near median |
| Neuthoprin | Azathioprine | 50 mg | Tablet | 100's | 091493 | PKR 3,516.04 | PKR 35.16/tablet | 64% above median |
| Neuthoprin | Azathioprine | 50 mg | Tablet | 10's | 091493 | PKR 350.91 | PKR 35.09/tablet | 64% above median |
| Neutia | Loratadine | 5 mg/5 mL | Suspension | 30ml | 038882 | PKR 49.87 | PKR 1.66/mL | 16% below median |
| Neutim Dry | Ceftazidime | 250 mg | Injection | Vial | 038852 | PKR 167.85 | PKR 167.85/vial/unit | Near median |
| Neutim Dry | Ceftazidime | 500 mg | Injection | Vial | 038853 | PKR 255.31 | PKR 255.31/vial/unit | Near median |
| Neutim Dry | Ceftazidime | 1 g | Injection | Vial | 038854 | PKR 479.57 | PKR 479.57/vial/unit | Near median |
| Neuto-Dop 5ml | Dopamine HCl | 40 mg | Injection | 10'sx5mlLDPE | 109655 | PKR 1,050.48 | — | No comparator |
| Neutolev | Levetiracetam | 500 mg/5 mL | IV injection/infusion | 1'sLDPE | 109657 | PKR 470.63 | — | No comparator |
| Neutolev | Levetiracetam | 500 mg/5 mL | Injection | 1'sLDPE | 109657 | PKR 470.63 | — | No comparator |
| Neutorit | Lopinavir + Ritonavir | 100 mg + 25 mg | Tablet | 120's | 111906 | PKR 8,957.74 | PKR 74.65/tablet | Near median |
| Neutovaric | Varenicline | 1 mg | Tablet | 28's | 110621 | PKR 3,015.26 | PKR 107.69/tablet | 18% below median |
| Neutrazol | Anastrozole | 1 mg | Tablet | 28's | 091492 | PKR 9,550.61 | PKR 341.09/tablet | Near median |
| Neutrocort | Hydrocortisone | 100 mg | Injection | 1's | 135791 | PKR 63.50 | PKR 63.50/vial/unit | 49% below median |
| Neutrocort | Hydrocortisone | 250 mg | Injection | 1's | 135792 | PKR 111.00 | PKR 111.00/vial/unit | 37% below median |
| Neutrocort | Hydrocortisone | 500 mg | Injection | 1's | 135793 | PKR 239.00 | PKR 239.00/vial/unit | 55% below median |
| Neutrocort-T | Hydrocortisone | 10 mg | Tablet | 3x10's | 135794 | PKR 120.00 | PKR 4.00/tablet | 29% below median |
| Neutroline | Water for Injection | 10 mL | IM/IV injection | 1x10ml | 038835 | PKR 10.60 | PKR 1.06/mL | No comparator |
| Neutroline | Water for Injection | 5 mL | IM/IV injection | 1x5ml | 038835 | PKR 6.15 | PKR 1.23/mL | No comparator |
| Neutroline | Water for Injection | 5 mL | Injection | 100's | 096697 | PKR 1,138.62 | PKR 11.39/vial/unit | 20% below median |
| Neutroline | Water for Injection | 10 mL | Injection / diluent | 1's | 096698 | PKR 23.30 | PKR 23.30/vial/unit | 21% above median |
| Neutroline | Water for Injection | 20 mL presentation | Injection / diluent | 1's | 096699 | PKR 31.06 | PKR 31.06/vial/unit | No comparator |
| Neutronem | Meropenem | 1 g | Sterile powder for injection | 1's | 116705 | PKR 4,187.68 | PKR 4,187.68/vial/unit | No comparator |
| Neutronem | Meropenem | 500 mg | Injection | 1's | 116706 | PKR 2,240.41 | PKR 2,240.41/vial/unit | 8% above median |
| Neutrorit 200 | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 109764 | PKR 10,849.30 | PKR 90.41/tablet | 6% below median |
| Neutrozol | Metronidazole | 500 mg | IV infusion | 100ml | 046878 | PKR 189.93 | PKR 1.90/mL | Near median |
| Neuvanco concentrate for | Vancomycin | 500 mg | Injection | 10's | 108297 | PKR 1,136.76 | PKR 113.68/vial/unit | 91% below median |
| Neuvir | Aciclovir | 500 mg | Injection | 1's | 097654 | PKR 1,261.97 | PKR 1,261.97/vial/unit | No comparator |
| Neuvir | Aciclovir | 250 mg | Lyophilized injection | 1's | 097659 | PKR 757.18 | PKR 757.18/vial/unit | Near median |
| Niftran | Nitrofurantoin | 100 mg | Tablet | 100's | 091487 | PKR 292.45 | PKR 2.92/tablet | 9% above median |
| Nlyte | Dextrose + Sodium chloride | NaCl 0.9g + Dextrose 5g/100 mL | IV infusion | 500ml | 088574 | PKR 119.36 | PKR 0.24/mL | 20% below median |
| Nlyte | Dextrose + Sodium chloride | NaCl 0.3g + Dextrose 3.3g/100 mL | IV infusion | 500ml | 088575 | PKR 75.80 | PKR 0.15/mL | 6% above median |
| Nlyte | Dextrose + Sodium chloride | NaCl 0.45g + Dextrose 5.0g/100 mL | IV infusion | 500ml | 088576 | PKR 139.85 | PKR 0.28/mL | 5% above median |
| Nlyte | Dextrose + Sodium chloride | NaCl 0.45g + Dextrose 10g/100 mL | IV infusion | 500ml | 093746 | PKR 115.00 | PKR 0.23/mL | No comparator |
| Nlyte | Dextrose + Sodium chloride | NaCl 0.9g + Dextrose 10g/100 mL | IV infusion | 500ml | 093747 | PKR 115.00 | PKR 0.23/mL | No comparator |
| Nlyte | Dextrose + Sodium chloride | 3.3% + 0.3% | IV infusion | 1000ml | 101517 | PKR 105.41 | PKR 0.11/mL | Near median |
| NubarbiSource observed | Phenobarbital | 20 mg/5 mL | Held for normalizationSource reported: Tablet · structural field conflict | 60ml | 064918Official source ↗ | No indexed price | — | — |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.